Corona Remedies Commences EU-GMP Approved Women's Hormone Facility

Corona Remedies Ltd has announced the inauguration and commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad. This state-of-the-art facility is designed for specialized hormone manufacturing, featuring segregated operations, precision environmental controls, and advanced containment technologies. It supports multiple dosage forms including tablets, soft gel capsules, ointments, and gels, with an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. The facility's commissioning is expected to increase Corona Remedies' in-house hormone manufacturing capacity by nearly 20%, reinforcing its commitment to women's healthcare and strengthening its capabilities for domestic and international markets.